A novel β-TrCP1/NRF2 interaction inhibitor for effective anti-inflammatory therapy
Open Access
- 11 July 2025
- journal article
- research article
- Published by Springer Nature in Journal of Biomedical Science
- Vol. 32 (1) , 1-19
Abstract
Background: Non-communicable chronic diseases are characterized by low-grade inflammation and oxidative stress. Extensive research has identified the transcription factor NRF2 as a potential therapeutic target. Current NRF2 activators, designed to inhibit its repressor KEAP1, often exhibit undesirable side effects. As an alternative approach, we previously developed PHAR, a protein–protein interaction inhibitor of β-TrCP1/NRF2, which promotes NRF2 activation. Using the same in silico screening platform, we have now identified a novel compound, P10. This small molecule selectively interferes with the β-TrCP1/NRF2 interaction, leading to NRF2 stabilization and transcriptional activation of its target genes in a β-TrCP1-dependent manner, demonstrating promising effects in a liver model of acute inflammation. Methods: After an in silico screening of ∼1 million compounds, including molecular docking analysis, ADMET evaluation, and molecular dynamics simulations, we identified and characterized a novel small molecule, P10, which inhibits β-TrCP1/NRF2 interaction. The compound was validated using luciferase reporter assays, co-immunoprecipitation, and ubiquitination experiments. The specificity of P10 was assessed by comparing NRF2 signatures in wild-type and Nrf2-null cells. The impact of NRF2 activation induced by P10 was investigated by evaluating its antioxidant and anti-inflammatory responses against tert-butyl hydroperoxide and lipopolysaccharide, respectively. Finally, wild-type and Nrf2-null mice were administered P10 intraperitoneally at a dose of 20 mg/kg daily for five consecutive days. Four hours before sacrifice, all animals received a lipopolysaccharide (LPS) injection at 10 mg/kg. Results: P10 selectively disrupts the interaction between β-TrCP1 and NRF2, thereby inhibiting β-TrCP1-mediated ubiquitination of NRF2 and leading to the upregulation of NRF2 target genes. Additionally, P10 mitigates oxidative stress induced by tert-butyl hydroperoxide and reduces pro-inflammatory markers in an NRF2-dependent manner in macrophages treated with lipopolysaccharide. In a preclinical model of liver inflammation, P10 specifically targets the liver, significantly attenuating lipopolysaccharide-induced inflammation through the activation of NRF2. This is demonstrated by decreased expression of inflammatory cytokine genes and a reduction in F4/80-stained liver macrophages. Notably, this anti-inflammatory effect is absent in Nrf2-knockout mice, confirming its NRF2-dependent mechanism of action. Conclusions: P10 emerges as a promising NRF2 activator by selectively disrupting the β-TrCP1/NRF2 interaction, highlighting its potential as a therapeutic agent for diseases presenting acute liver inflammation. GraphicalKeywords
Funding Information
- Agencia Estatal de Investigación (PDC2021-121421-I00, PDC2022-1337665-I00, PID2022-141786OB-I00, PID2019-110061RB-I00)
- Comunidad de Madrid (S2017BMD-3827, P2022_BMD-7230)
This publication has 77 references indexed in Scilit:
- Electrophilic metabolites targeting the KEAP1/NRF2 partnershipCurrent Opinion in Chemical Biology, 2024
- KEAP1‐NRF2 protein–protein interaction inhibitors: Design, pharmacological properties and therapeutic potentialMedicinal Research Reviews, 2022
- α-Synuclein Induces the GSK-3-Mediated Phosphorylation and Degradation of NURR1 and Loss of Dopaminergic HallmarksMolecular Neurobiology, 2021
- Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study)Annals of Neurology, 2020
- Keap1, the cysteine-based mammalian intracellular sensor for electrophiles and oxidantsArchives of Biochemistry and Biophysics, 2017
- Nrf2 Induces IL-17D to Mediate Tumor and Virus SurveillanceCell Reports, 2016
- Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's diseaseGlia, 2009
- Redox‐sensitive regulation of gene expression in human primary macrophages exposed to inorganic arsenicJournal of Cellular Biochemistry, 2009
- GS143, an IκB ubiquitination inhibitor, inhibits allergic airway inflammation in miceBiochemical and Biophysical Research Communications, 2008
- A novel small-molecule inhibitor of NF-κB signalingBiochemical and Biophysical Research Communications, 2008